Evenity launching in USA with a $21,900/year price tag

Following swiftly on its US regulatory approval last week, biotech major Amgen (Nasdaq: AMGN) yesterday announced that its Evenity (romosozumab-aqqg) is now available for shipment to wholesalers in the USA.

Evenity’s US approval is for the treatment of osteoporosis in postmenopausal women at high risk for fracture and is a successor to s a successor to the company’s $2 billion a year osteoporosis blockbuster Prolia (denosumab), which is approaching patent expiry.

"Osteoporosis is a silent disease that can lead to devastating consequences. Unfortunately, only 20 percent of women who have experienced a fracture receive any type of osteoporosis treatment post-fracture," said Murdo Gordon, executive vice president of global commercial operations at Amgen. "This is unacceptable for the millions of women who have suffered from an osteoporosis-related fracture. We need to urgently make postmenopausal osteoporosis a women's health priority," he added.